相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
Anna Jamnitski et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
P. P. Tak et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Maya H. Buch et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
Katerina Chatzidionysiou et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
B Cell Activation Biomarkers as Predictive Factors for the Response to Rituximab in Rheumatoid Arthritis
Jeremie Sellam et al.
ARTHRITIS AND RHEUMATISM (2011)
Body Mass Index and Clinical Response to Infliximab in Rheumatoid Arthritis
Ruth Klaasen et al.
ARTHRITIS AND RHEUMATISM (2011)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register
Wietske Kievit et al.
RHEUMATOLOGY (2011)
The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study
Ruth Klaasen et al.
RHEUMATOLOGY (2011)
Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
G. M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial
Arno W. R. van Kuijk et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Relationship Between the Type I Interferon Signature and the Response to Rituximab in Rheumatoid Arthritis Patients
Rogier M. Thurlings et al.
ARTHRITIS AND RHEUMATISM (2010)
Management of Nonresponse to Rituximab in Rheumatoid Arthritis Predictors and Outcome of Re-treatment
E. M. Vital et al.
ARTHRITIS AND RHEUMATISM (2010)
Synovial Tissue Heterogeneity in Rheumatoid Arthritis in Relation to Disease Activity and Biomarkers in Peripheral Blood
Lisa G. M. van Baarsen et al.
ARTHRITIS AND RHEUMATISM (2010)
Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry
Roberto Caporali et al.
AUTOIMMUNITY REVIEWS (2010)
CD11c as a Transcriptional Biomarker to Predict Response to Anti-TNF Monotherapy With Adalimumab in Patients With Rheumatoid Arthritis
B. Stuhlmueller et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial
Philip J. Mease et al.
JOURNAL OF RHEUMATOLOGY (2010)
The Gene Expression Profile in the Synovium as a Predictor of the Clinical Response to Infliximab Treatment in Rheumatoid Arthritis
Johan Lindberg et al.
PLOS ONE (2010)
Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers
Thomas Doerner et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
C. Potter et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation
Y. K. O. Teng et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
The Relationship Between Synovial Lymphocyte Aggregates and the Clinical Response to Infliximab in Rheumatoid Arthritis A Prospective Study
Ruth Klaasen et al.
ARTHRITIS AND RHEUMATISM (2009)
Synovial Tissue Sublining CD68 Expression Is a Biomarker of Therapeutic Response in Rheumatoid Arthritis Clinical Trials: Consistency Across Centers
Barry Bresnihan et al.
JOURNAL OF RHEUMATOLOGY (2009)
Golimumab inpatients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
Josef S. Smolen et al.
LANCET (2009)
Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis
Valerie Badot et al.
ARTHRITIS RESEARCH & THERAPY (2009)
The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium
C. A. Wijbrandts et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Disease Activity-Guided Rituximab Therapy in Rheumatoid Arthritis The Effects of Re-Treatment in Initial Nonresponders Versus Initial Responders
Rogier M. Thurlings et al.
ARTHRITIS AND RHEUMATISM (2008)
Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype
Rogier M. Thurlings et al.
ARTHRITIS AND RHEUMATISM (2008)
Analysis of Apoptosis in Peripheral Blood and Synovial Tissue Very Early After Initiation of Infliximab Treatment in Rheumatoid Arthritis Patients
Carla A. Wijbrandts et al.
ARTHRITIS AND RHEUMATISM (2008)
Modulation of CCR2 in rheumatoid arthritis - A double-blind, randomized, placebo-controlled clinical trial
Clarissa E. Vergunst et al.
ARTHRITIS AND RHEUMATISM (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Responsiveness to anti-tumour necrosis factor α therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients
T. C. van der Pouw Kraan et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Treatment response to a second or third TNF-inhibitor in RA:: results from the South Swedish Arthritis Treatment Group Register
J. A. Karisson et al.
RHEUMATOLOGY (2008)
Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results
A. Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response
R. M. Thurlings et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Expression of a pathogen-response program in peripheral blood cells defines a subgroup of Rheumatoid Arthritis patients
T. C. T. M. van der Pouw Kraan et al.
GENES AND IMMUNITY (2008)
Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment
Y. K. Onno Teng et al.
ARTHRITIS AND RHEUMATISM (2007)
Distinctive gene expression signatures in rheumatoid arthritis synovial tissue fibroblast cells: correlates with disease activity
C. L. Galligan et al.
GENES AND IMMUNITY (2007)
Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients
T. C. T. M. van der Pouw Kraan et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice
S. Bombardieri et al.
RHEUMATOLOGY (2007)
Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis
Koen Vos et al.
ARTHRITIS AND RHEUMATISM (2007)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Lack of efficacy of a third tumour necrosis factor α antagonist after failure of a soluble receptor and a monoclonal antibody
E. Solau-Gervais et al.
RHEUMATOLOGY (2006)
Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset
E Berglin et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
GJ Wolbink et al.
ARTHRITIS AND RHEUMATISM (2006)
Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles
SP Linn-Rasker et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients
Johan Lindberg et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis
JJ Haringman et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity - Evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis
PV Kasperkovitz et al.
ARTHRITIS AND RHEUMATISM (2005)
Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response
H Marotte et al.
ARTHRITIS RESEARCH & THERAPY (2005)
Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis
FA van Gaalen et al.
ARTHRITIS AND RHEUMATISM (2004)
Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis
DM Gerlag et al.
ARTHRITIS AND RHEUMATISM (2004)
A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis
L Padyukov et al.
ARTHRITIS AND RHEUMATISM (2004)
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
BA van de Putte et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Tumor necrosis factor a blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue
TJM Smeets et al.
ARTHRITIS AND RHEUMATISM (2003)
Rheumatoid arthritis is a heterogeneous disease - Evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues
TCTMV Kraan et al.
ARTHRITIS AND RHEUMATISM (2003)
Clinical responses to tumor necrosis factor α antagonists do not show a bimodal distribution -: Data from the Stockholm tumor necrosis factor α followup registry
RF van Vollenhoven et al.
ARTHRITIS AND RHEUMATISM (2003)
Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies
MD Smith et al.
RHEUMATOLOGY (2001)
The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis
G Cunnane et al.
RHEUMATOLOGY (2001)
Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis:: potential implications for treatment
AK Ulfgren et al.
ANNALS OF THE RHEUMATIC DISEASES (2000)
分享论文
